The Clinical Times
The Front Page of Medicine

Latest medical news · page 74

The latest headlines across every section, pulled from official and open-access sources.

ACP · Jul 13, 2026

ACP says underregulated dietary supplements endanger public health

PHILADELPHIA, July 13, 2026—Dietary supplements must be more regulated to protect public health, says the American College of Physicians (ACP). In a new paper, “ Modernizing the Regulatory Framework for Dietary Supplements: A Position Paper from the American College of Physicians ” published today in Annals of Internal Medicine , ACP issues recommendations to strengthen and modernize the manufacturing and marketing of dietary supplements. Over half of adults in the United States consume dietary supplements, but only one quarter consume supplements that have been recommended by a health care…

ACC (Cardiology) · Jul 13, 2026

ACC, Other CV Societies Urge Withdrawal of OMB Research Funding Proposal

The ACC, joined by the American Society of Echocardiography, the American Society of Nuclear Cardiology, the Society for Cardiovascular Angiography & Interventions, and the Society of Cardiovascular Computed Tomography, has submitted comments to the Office of Management and Budget (OMB) expressing significant concerns with proposed revisions to the Uniform Guidance governing federal financial assistance programs.

MedCity News · Jul 13, 2026

Healthcare Must Protect Innovation, Not Just Patient Data

Healthcare cybersecurity is no longer just about protecting electronic health records. It is increasingly about protecting the research, algorithms, clinical data, and intellectual property that drive the next generation of medicine. The post Healthcare Must Protect Innovation, Not Just Patient Data appeared first on MedCity News .

FDA Drugs · Jul 13, 2026

Complex Generics News

Generally, complex generics are products that have complex active ingredients, formulations, dosage forms, or routes of administration, or are complex drug-device combination products. Generics of complex brand name drugs (i.e., reference listed drugs) can be more difficult to develop.

PLOS Medicine · Jul 13, 2026

Self-explaining artificial intelligence for the classification of B cell non-Hodgkin lymphoma: A diagnostic decision support study

by Michael C. Thrun, Jörg Hoffmann, Stefan W. Krause, Peter Krawitz, Quirin Stier, Andreas Neubauer, Cornelia Brendel, Alfred Ultsch Background Multiparameter flow cytometry is a cornerstone of B cell non-Hodgkin lymphoma (B-NHL) diagnostics, but interpretation requires substantial expertise and is complicated by high-dimensional data, variable sample quality, limited data for rare entities, and evolving clinical classification systems. Current artificial intelligence approaches often require large training datasets and provide limited insight into the rationale behind individual diagnostic…

FDA Drugs · Jul 13, 2026

Psychedelic Drugs

FDA is supporting the development of psychedelic drugs, including new treatments for serious mental health conditions.

FDA Drugs · Jul 13, 2026

MOU 225-26-007

This Memorandum of Understanding ("MOU") between the U.S. Department of Health and Human Services (HHS), the U.S. Food and Drug Administration (FDA), and the U.S. Department of Veterans Affairs (VA) (hereafter “the Parties” or “Federal Partners”) provides a framework for collaboration and the exchan

← NewerOlder →

Back to the live front page